Abstract
Sclerosing epithelioid fibrosarcoma (SEF) is a rare and poorly defined variant of fibrosarcoma, but generally insensitive to chemotherapy and progresses with poor prognosis. We report the marvelous effect of irinotecan hydrochloride (CPT-11) chemotherapy in rescuing a patient with atypical SEF from emergent condition, who underwent recurrences after several treatment methods. Small dose of CPT-11 was administered to the patient, with which, the size of superficial mass (cervical lymph node) gradually decreased observed by the naked eyes in 5 days. Xray and CT image proved a marked reduction in the size of the tumor. CPT-11 is valuable for the treatment of this aggressive sarcoma. In condition of emergency caused by sarcoma oppression, administering a tolerable small dose of topoisomerase I-inhibiting drug could be a beneficial choice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ossendorf C, Studer GM, Bode B, et al. Sclerosing epithelioid fibrosarcoma: case presentation and a systematic review. Clin Orthop Relat Res 2008; 466:1485–1491.
Antonescu CR, Rosenblum MK, Pereira P, et al. Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol 2001; 25:699–709.
Karavasilis V, Seddon BM, Ashley S, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008; 112:1585–1591.
Minchom A, Jones RL, Fisher C, et al. Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma 2010; 2010:264360.
Meis-Kindblom JM, Kindblom LG, Enzinger FM. Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma. Am J Surg Pathol 1995; 19:979–993.
Patro BS, Frohlich R, Bohr VA, et al. WRN helicase regulates the ATRCHK1-induced S-phase checkpoint pathway in response to topoisomerase-I-DNA covalent complexes. J Cell Sci 2011; 124:3967–3979.
Zhao H, Rybak P, Dobrucki J, et al. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. Cytometry A 2012; 81:45–51.
Regairaz M, Zhang YM, Fu H, et al. Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol 2011; 195:739–749.
Manita D, Toba Y, Takakusagi Y, et al. Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction. Bioorg Med Chem 2011; 19:7690–7697.
Slatter JG, Su P, Sams JP, et al. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997; 25:1157–1164.
Ong SY, Clarke SJ, Bishop J, et al. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anticancer Drugs 2001; 12:619–625.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a grant from Science and Technology Committee of Guangdong (No.2010B060900093) and a grant from Educational Commission of Guangzhou (No.10A196). Contributed equally to this study.
Rights and permissions
About this article
Cite this article
Pan, Ch., Han, Xq. & Li, Js. CPT-11 chemotherapy rescued a patient with atypical sclerosing epithelioid fibrosarcoma from emergent condition. Chin. J. Cancer Res. 24, 253–256 (2012). https://doi.org/10.1007/s11670-012-0253-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11670-012-0253-1